Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024年2月16日 - 6:10AM
ビジネスワイヤ(英語)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST
on Thursday, February 29, 2024, following the release of its fourth
quarter and full year 2023 financial results.
The call may be accessed by dialing (877) 709-8150 (domestic) or
(201) 689-8354 (international). Please dial in at least 10 minutes
in advance and inform the operator that you would like to join the
“Puma Biotechnology Conference Call.” A live webcast of the
conference call and presentation slides may be accessed on the
Investors section of the Puma Biotechnology website at
https://www.pumabiotechnology.com. A replay of the call will be
available approximately one hour after completion of the call and
will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licensed the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in 2017 for
the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also
approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic
HER2-positive breast cancer who have received two or more prior
anti-HER2-based regimens in the metastatic setting. NERLYNX was
granted marketing authorization by the European Commission in 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX® is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license
agreement for the development and commercialization of the
anti-cancer drug alisertib, a selective, small molecule, orally
administered inhibitor of aurora kinase A. Initially, Puma intends
to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer.
Further information about Puma Biotechnology may be found at
https://www.pumabiotechnology.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215062395/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 8 2024 まで 9 2024
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 9 2023 まで 9 2024